Caroline Seymour

Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.

CNS Pharmaceuticals has acquired the orphan drug designations for TPI 287 in gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.

Perioperative nivolumab plus chemotherapy was approved by the European Commission for use in resectable PD-L1–positive non–small cell lung cancer.

Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.

Durvalumab plus BCG induction and maintenance improved DFS vs BCG in these settings alone in patients with high-risk non–muscle-invasive bladder cancer.

Botensilimab and balstilimab proved active and safe as neoadjuvant therapy in patients with mismatch repair–deficient and –proficient solid tumors.

A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Patients with mCRPC enrolled in the phase 3 TALAPRO-2 trial harboring TMPRSS2-ERG fusions in ctDNA had a distinct tumor molecular profile vs those without.

Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.

Twelve-month RFS was associated with MRD status in patients with BCG-unresponsive, NMIBC who received treatment with cretostimogene grenadenorepvec.

Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.

High variability in sarcoma clinical trial funding, location, and phase was identified in a global analysis conducted over the past decade.

Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.

A clinical trial steering committee from the Mount Sinai Health System helped integrate therapeutic clinical trials into the SOC for patients with cancer.

Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.

Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.

Stable disease was common in patients with CD123-positive, relapsed/refractory acute myeloid leukemia who were treated with AFM28.

Orca-T led to lower rates of EBV and CMV reactivation vs CD34 engraftment in patients with select hematologic malignancies.

Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.

Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.

The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3 EQUATOR trial.

Bexobrutideg received orphan drug designation from the FDA for the treatment of patients with Waldenström macroglobulinemia.

Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.

Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

177Lu rhPSMA-10.1 injection led to proportionally higher absorbed radiation doses in tumors vs healthy tissues in patients with mCRPC.